Table 2 Clinical characteristics of patients with initial and secondary steroid resistance
Variables | I-SRNS (n = 182) | S-SRNS (n = 92) | P-value |
|---|---|---|---|
Age of onset (month), Median (Q1, Q3) | 59.00 (29.25, 98.75) | 53.00 (38.75, 84.00) | 0.841 |
Sex, n(%) | 0.030 | ||
Male | 126 (69.2) | 69 (75.0) | |
Female | 56 (30.8) | 23 (25.0) | |
Nation, n (%) | 0.043 | ||
Han | 108 (59.3) | 42 (45.7) | |
Zhuang | 60 (33.0) | 47 (51.1) | |
Others | 14 (7.2) | 3 (3.2) | |
Family history, n (%) | 25 (13.7) | 5 (5.4) | 0.019 |
Extra-kidney manifestations, n (%) | 23 (12.6) | 8 (8.7) | 0.103 |
24-hour urinary protein (mg), Median (Q1, Q3) | 2559.3 (1549.1, 3761.6) | 2588.05 (1832.7, 4181.9) | 0.201 |
Scr (µmol/l), Median (Q1, Q3) | 38.0 (25.0, 52.0) | 37.00 (27.75, 52.00) | 0.720 |
eGFR, Median (Q1, Q3) | 119.33 (88.1, 151.8) | 116.24 (98.7, 141.9) | 0.478 |
Hematuria, n (%) | 83 (45.6) | 22 (23.9) | < 0.001 |
Response to immune therapy, n (%) | < 0.001 | ||
Valid | 100 (54.9) | 71 (77.2) | |
Invalid | 65 (35.7) | 15 (16.3) | |
Complication | |||
Hypertension, n (%) | 37 (20.3) | 13 (14.1) | 0.147 |
AKI, n(%) | 18 (9.9) | 6 (6.5) | 0.688 |
Vitamin D deficiency, n (%) | 35 (19.2) | 22 (23.9) | 0.467 |
Ocular hypertension, n (%) | 22 (12.1) | 11 (12.0) | 1.000 |
Dwarfism, n(%) | 25 (13.7) | 16 (17.4) | 0.562 |
Follow-up time (month), Median (Q1, Q3) | 47.00 (27.25, 73.00) | 65.50 (45.75, 96.75) | < 0.001 |
Prognosis, n (%) | 0.034 | ||
Normal eGFR | 149 (81.9) | 87 (94.6) | |
CKD2-4 | 16 (8.8) | 4 (4.3) | |
CKD5 | 12 (6.6) | 1 (1.1) | |
Death | 3 (1.6) | 0 (0) | |
Lost follow-up | 2 (1.1) | 0 (0) |